CGA
SEEL

Crescent Grove Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Crescent Grove Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5
Closed -$3.68K – 301
2023
Q3 		$3.68K Buy
+5
New +$21.4K ﹤0.01% 270

Other funds holding SEEL

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crescent Grove Advisors's SEEL Position: Q4 2023 in Review

Crescent Grove Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 5 shares — an estimated $3.68K sold.

Crescent Grove Advisors first reported a position in SEEL in Q3 2023 and held it in 1 quarter. The position peaked at $3.68K in Q3 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • Crescent Grove Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Crescent Grove Advisors sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.68K.
  • Crescent Grove Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Crescent Grove Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $3.68K in Q3 2023.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Crescent Grove Advisors's 13F filing for Q4 2023, filed 30 Jan 2024.